Note: This document contains side effect information about idursulfase. Some of the dosage forms listed on this page may not apply to the brand name Elaprase.
Common side effects of Elaprase include: abscess, chest wall pain, dyspepsia, infusion related reaction, pruritic rash, pruritus, urticaria, and visual disturbance. See below for a comprehensive list of adverse effects.
Applies to idursulfase: intravenous solution
Intravenous route (Solution)
Life-threatening anaphylactic reactions, presenting as respiratory distress, hypoxia, hypotension, urticaria, and/or angioedema of throat or tongue have occurred in some patients during and up to 24 hours after idursulfase infusions, regardless of duration of the course of treatment. Closely observe patients during and after idursulfase administration and be prepared to manage anaphylaxis. Inform patients of the signs and symptoms of anaphylaxis and have them seek immediate medical care should symptoms occur. Patients with compromised respiratory function or acute respiratory disease may be at risk of serious acute exacerbation of their respiratory compromise due to hypersensitivity reactions, and require additional monitoring.
Along with its needed effects, idursulfase (the active ingredient contained in Elaprase) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking idursulfase:
Incidence not known
Some side effects of idursulfase may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Applies to idursulfase: intravenous solution
The most frequently reported adverse effects in all clinical trials were hypersensitivity reactions and included rash, urticaria, pruritus, flushing, pyrexia, and headache.
The most frequently reported adverse effects following treatment were hypoxia, pyrexia, rash, vomiting, diarrhea, cough, musculoskeletal pain, headache, pruritus, and urticaria.
In clinical trials, the most common adverse effects were hypersensitivity reactions and included rash, urticaria, pruritus, flushing, pyrexia, and headache. Most reactions were resolved with slowing the infusion rate or temporarily stopping the infusion, with or without additional treatments including antihistamines and/or corticosteroids prior to or during infusions.
Very common (10% or more): Hypersensitivity reaction
Frequency not reported: Anaphylactoid/anaphylactic reaction
Postmarketing reports: Late-emergent anaphylactoid reaction
In clinical trials, 32 out of 63 patients 5 years and older tested positive for antidrug antibodies at least 1 time; of the 32 patients, 23 tested positive for antidrug antibodies 3 or more times. The incidence of hypersensitivity reactions was higher in positive antidrug antibody patients than those who tested negative. Out of 32 antidrug antibody positive patients, 13 also tested positive for neutralizing antibodies. There was no clear relationship between presence of either type of antibody and therapeutic response.
Very common (10% or more): Antidrug antibody development (50%), neutralizing antibody development (24.3%)
Very common (10% or more): Headache (up to 65.6%)
Common (1% to 10%): Dizziness, tremor
Very common (10% or more): Rash (up to 34.4%), pruritus (up to 31.3%), urticaria (up to 16%)
Common (1% to 10%): Erythema
Very common (10% or more): Infusion-related reaction (68.8%), pyrexia (up to 62.5%), chest pain (up to 15.6%), infusion site swelling (12.5%)
Common (1% to 10%): Face edema, peripheral edema
The most serious infusion-related reactions included anaphylactoid/anaphylactic reactions. The most common infusion-related reactions included cutaneous reactions (rash, pruritus, urticaria), pyrexia, headache, hypertension, flushing, wheezing, hypoxia, dyspnea, abdominal pain, nausea, dyspepsia, chest pain, and infusion site swelling. Treatment/amelioration of infusion-related reactions included slowing the infusion rate, interrupting the infusion, or drug therapy (e.g., antihistamines, antipyretics, low-dose corticosteroids [prednisone, methylprednisolone], beta-agonist nebulization).
Very common (10% or more): Musculoskeletal pain (13%)
Common (1% to 10%): Arthralgia
Very common (10% or more): Abdominal pain (up to 53.1%), nausea (up to 28.1%), dyspepsia (12.5%), vomiting, diarrhea
Common (1% to 10%): Swollen tongue
Very common (10% or more): Hypertension (up to 25%), flushing (15.6%)
Common (1% to 10%): Cyanosis, arrhythmia, tachycardia, hypotension
Postmarketing reports: Cardiac failure, cardiorespiratory arrest
Very common (10% or more): Wheezing (15.6%), dyspnea (up to 12.5%)
Common (1% to 10%): Cough, bronchospasm, tachypnea, hypoxia
Frequency not reported: Pulmonary embolism
Postmarketing reports: Respiratory failure, respiratory distress, pneumonia
Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.
Source: Drugs.com Elaprase